Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma | Zendy

Cheng Ji | Zendy; Fengtao You | Zendy; Tingting Zhang | Zendy; Shuangshuang Fan | Zendy; Zhichao Han | Zendy; Shufen Xiang | Zendy; Yinyan Wang | Zendy; Binjie Sheng | Zendy; Tian Wang | Zendy; Gangli An | Zendy; Huimin Meng | Zendy; Lin Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Novel anti-GD2 CAR-T cells exhibit superior cytotoxicity against neuroblastoma

Author(s) -

Cheng Ji,

Fengtao You,

Tingting Zhang,

Shuangshuang Fan,

Zhichao Han,

Shufen Xiang,

Yinyan Wang,

Binjie Sheng,

Tian Wang,

Gangli An,

Huimin Meng,

Lin Yang

Publication year - 2020

Publication title -

european journal of inflammation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.219

H-Index - 20

eISSN - 2058-7392

pISSN - 1721-727X

DOI - 10.1177/2058739220961193

Subject(s) - chimeric antigen receptor , neuroblastoma , in vivo , in vitro , potency , cytotoxicity , ganglioside , antigen , cancer research , chemistry , t cell , pharmacology , medicine , immunology , cell culture , biology , immune system , biochemistry , microbiology and biotechnology , genetics

Treatment of high-risk paediatric neuroblastoma represents an unmet clinical need. Chimeric antigen receptor-modified T cell (CAR-T) therapy is a promising treatment option, but there exist some challenges regarding specificity and potency. The current study used ganglioside GD2 as a target for CAR-T construction because of its selective overexpression in neuroblastoma cells. We engineered a GD2-based CAR-T construct, including ICOS and 4-1BB co-stimulatory domains for better persistence. The cytotoxicity of the generated CAR-T cells (PG3-GD2-CAR-T) was verified using in vitro and in vivo assays. PG3-GD2-CAR-T cells exerted potent anti-tumour activity in vitro and in vivo, with minimal effects on peripheral blood cells. PG3-GD2-CAR-T cells exhibited encouraging specificity for and potency against neuroblastoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research